Takeda introduces Edarbyclor drug in US
Japan's Takeda Pharmaceutical has announced that its Edarbyclor (azilsartan medoxomil and chlorthalidone) is now available by prescription in US pharmacies for the treatment of hypertension to lower blood pressure in adults.
Edarbyclor is a fixed-dose combination of two medications: azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a long-acting diuretic used in the treatment of hypertension.
In a phase 3 clinical trial, Edarbyclor (40/25 mg) was found to reduce systolic blood pressure compared to the fixed-dose combination of olmesartan medoxomil-hydrochlorothiazide at its maximum dose (40/25 mg).
In December 2011, the US Food and Drug Administration approved Edarbyclor at a recommended starting dose of 40/12.5 mg and a maximal dose of 40/25 mg.
The company said Edarbyclor may be used in patients not adequately controlled with monotherapy and as an initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals.
Related Insight
Suppliers Directory
Pro-Active Translations- Language Translations Specialist for Life Sciences
PA Translations focuses on providing best-in-class specialized translation services for companies in the pharmaceutical, medical device and laboratory instrument, and healthcare sectors in up to 75 languages.
Drug Research > Drug Discovery & Development > Suppliers
Kuecept - Concept Formulation Design
Kuecept Ltd is a specialist pharmaceutical contract research organisation supporting clients with the early phase development of low solubility, poorly bioavailable compounds. Our patented drug delivery technologies and formulation expertise in oral and parenteral dosage form design and development are used to fast track compounds through preclinical efficacy studies and toxicity testing and into clinic with robust, stable and improved performance products.
Drug Research > Drug Discovery & Development > Suppliers
Centre for Human Drug Research - Early Phase Drug Development
The Centre for Human Drug Research (CHDR) performs clinical studies of innovative medicines with the concept where the maximum amount of information is extracted in the earliest clinical phase, using innovative and complex techniques as reflected in our publication output.
Drug Research > Drug Discovery & Development > Suppliers
Biospectra - High Purity Biological Buffers
Biospectra manufactures high purity biological buffers specifically intended for use in biopharm applications.
Drug Research > Drug Discovery & Development > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Discovery & Development Intelligence
Eurand: Research and Development Experts
Published by Aptalis Pharmaceutical Technologies (formerly Eurand)
Drug Research > Drug Discovery & Development > White Papers
Highly Automated ECG Analysis
Published by Celerion
Drug Research > Drug Discovery & Development > White Papers
Company Brochure
Published by ZoBio
Drug Research > Drug Discovery & Development > White Papers
Understanding Pasteurisation and Sterilisation Processes
Published by Tecnosoft
Drug Research > Drug Discovery & Development > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.